3Biotech

An article describing the development of ACT017, a first in class antithrombotic agent developped by Acticor-Biotech :
http://www.tandfonline.com/doi/full/10.1080/19420862.2017.1336592

Design, development and characterization of ACT017, a humanized Fab that blocks platelet's glycoprotein VI function without causing bleeding risks (2017). Design, development and characterization of ACT017, a humanized Fab that blocks platelet's glycoprotein VI function without causing bleeding risks. mAbs. Ahead of Print. doi: 10.1080/19420862.2017.1336592

3Biotech will attend the Third Annual European CMO consulting Summit in Copenhagen , 19-21 May. This summit is organized by CMC Biologics.

We are selected for Biovision catalyzer.

3Biotech has been selected to represent the project "Radical Imaging" at the Biovision Catalyzer the 15-16th of April at Lyon. Radical Imaging is an innovative project in the metabolic imaging to detect cancers via Magnetic Resonance Imaging.

The selection committees have identified 25 companies seeking funding for the Investor Conference and 25 innovative projects for the Catalyzer session.

3Biotech will at Bio-Europe 2015 the 9-11 of March at Paris